Loading…
Impact BioMedical Inc. is projected to decline to $0.4124 by 2027, a -7% move from its current price of $0.442. IBO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.423 | $0.4419 | $0.4617 | -0.02% |
| Jul 13 | $0.4153 | $0.4418 | $0.47 | -0.04% |
| Jul 14 | $0.4095 | $0.4417 | $0.4765 | -0.06% |
| Jul 15 | $0.4046 | $0.4416 | $0.482 | -0.09% |
| Jul 16 | $0.4004 | $0.4415 | $0.4869 | -0.11% |
| Jul 17 | $0.3966 | $0.4414 | $0.4914 | -0.13% |
| Jul 18 | $0.3931 | $0.4413 | $0.4955 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3931 | $0.4413 | $0.4955 | -0.15% |
| Week 2 | $0.3741 | $0.4407 | $0.519 | -0.30% |
| Week 3 | $0.3601 | $0.44 | $0.5377 | -0.45% |
| Week 4 | $0.3486 | $0.4393 | $0.5538 | -0.60% |
| Week 5 | $0.3386 | $0.4387 | $0.5683 | -0.75% |
| Week 6 | $0.3299 | $0.438 | $0.5816 | -0.90% |
| Week 7 | $0.322 | $0.4374 | $0.5941 | -1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electropholically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.
It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients.
Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.
Impact BioMedical Inc. (IBO) is a healthcare company focused on discovering, developing, and commercializing products across specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness in the United States. The stock trades at $0.4517 and has a market capitalization of $48.7M, ranking 4588.
The current price and the stake in its market position are paired with a forecast that shows varying upside by year, including bullish periods in the later years. The stock carries a relatively low current price relative to its long-run forecast path, with a 30-day technical picture that frames the near-term setup. Overall, the outlook suggests upside potential over the extended horizon, though estimates remain subject to uncertainty and do not constitute guarantees.
A major floor 21.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 32.4% above — a clean break opens room to run.
A major ceiling 76.5% above — clearing it would confirm fresh momentum.
Key IBO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4552 | Sell | $0.4543 | Sell |
| MA 10 | $0.4666 | Sell | $0.4681 | Sell |
| MA 20 | $0.5016 | Sell | $0.4913 | Sell |
| MA 50 | $0.546 | Sell | $0.5295 | Sell |
| MA 100 | $0.5596 | Sell | $0.5465 | Sell |
| MA 200 | $0.5413 | Sell | $0.6124 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.91 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -104.40 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -17.84 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.66 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 39.10 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.44 | Sell |
| ADX (14) | 17.76 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is neutral with RSI14 at 40, indicating balanced momentum. Moving averages show SMA50 at $0.5585 and SMA200 at $0.5446, placing near-term resistance above the current price and a support level around $0.452.
The stock’s 30-day range runs from $0.3381 to $0.6034, highlighting a relatively wide swing within the near term. Given the current price of $0.4517, the instrument sits around the nearby support level, suggesting limited downside risk in the very near term if support holds, with resistance near $0.585 on the upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.401 | $0.442 | $0.5979 | 0% | Neutral | |
| $0.31 | $0.4124 | $0.5901 | -7% | Neutral | |
| $0.372 | $0.5191 | $0.7843 | +17% | Neutral | |
| $0.3979 | $0.5783 | $0.9112 | +31% | Bullish | |
| $0.3953 | $0.5957 | $0.9719 | +35% | Bullish | |
| $0.3762 | $0.5862 | $0.9857 | +33% | Bullish | |
| $0.2923 | $0.47 | $0.812 | +6% | Neutral | |
| $0.3206 | $0.5314 | $0.9403 | +20% | Bullish | |
| $0.3943 | $0.6728 | $1.22 | +52% | Bullish | |
| $0.3925 | $0.6888 | $1.27 | +56% | Bullish | |
| $0.3997 | $0.8012 | $1.61 | +81% | Bullish | |
| $0.5737 | $1.27 | $2.89 | +188% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.401 | $0.442 | $0.5372 | +0.00% |
| August 2026 | $0.354 | $0.4248 | $0.5284 | -3.89% |
| September 2026 | $0.3571 | $0.4334 | $0.5484 | +2.02% |
| October 2026 | $0.3819 | $0.4681 | $0.601 | +8.02% |
| November 2026 | $0.381 | $0.4709 | $0.6119 | +0.59% |
| December 2026 | $0.3653 | $0.4551 | $0.5979 | -3.36% |
Click any year to see its month-by-month IBO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Impact BioMedical Inc.'s 2026 outlook centres on $0.442, within a $0.401 to $0.5979 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, IBO could reach as high as $0.5901, with a base case around $0.4124 and support toward $0.31 — roughly -7% from $0.442. Price action looks broadly range-bound.
Expect IBO to range from $0.372 to $0.7843 through 2028. The $0.5191 average target implies a +17% move from current prices. That is up +26% on the projected 2027 average. A consolidation phase looks the most probable path here.
The IBO price prediction for 2029 points to an average of $0.5783 (low $0.3979, high $0.9112) — a potential gain of +31% on today's $0.442. Momentum favours further upside here.
In 2030, IBO is projected to trade between $0.3953 and $0.9719, averaging $0.5957 — a potential gain of +35% from today's $0.442. That is up +3% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Impact BioMedical Inc.'s 2031 outlook centres on $0.5862, within a $0.3762 to $0.9857 range. That is -2% versus the projected 2030 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2032, IBO could reach as high as $0.812, with a base case around $0.47 and support toward $0.2923 — roughly +6% from $0.442. A consolidation phase looks the most probable path here.
Expect IBO to range from $0.3206 to $0.9403 through 2033. The $0.5314 average target implies a +20% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The IBO price prediction for 2034 points to an average of $0.6728 (low $0.3943, high $1.22) — a potential gain of +52% on today's $0.442. Buyers look set to stay in control over this stretch.
In 2035, IBO is projected to trade between $0.3925 and $1.27, averaging $0.6888 — a potential gain of +56% from today's $0.442. That is up +2% on the projected 2034 average. Momentum favours further upside here.
Impact BioMedical Inc.'s 2040 outlook centres on $0.8012, within a $0.3997 to $1.61 range. That is up +16% on the projected 2035 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, IBO could reach as high as $2.89, with a base case around $1.27 and support toward $0.5737 — roughly +188% from $0.442. Momentum favours further upside here.
Investing $1,000 in IBO today (≈ 2,262.443439 IBO) could be worth
$2,884.42
+$1,884.42 (+188%) by 2050 · US Dollar
Based on the average projected IBO price of $1.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBOwould be worth at today's price.
$1,000 invested in IBO on Jul 10, 2025 (≈ 1,745.200656 IBO) would be worth
$771.38
-$228.62 (-22.9%) today · 0.77× · US Dollar
Based on a IBO entry price of $0.573 vs. today's $0.442.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.472 | $936.44 | -6.4% |
| 1 month ago | $0.569 | $776.8 | -22.3% |
| 3 months ago | $0.688 | $642.44 | -35.8% |
| 6 months ago | $0.485 | $911.34 | -8.9% |
| 1 year ago | $0.573 | $771.38 | -22.9% |
| All time (1.8y) ago | $2.68 | $164.93 | -83.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBO forecast.
Our base-case forecast reaches $0.88 around 2050.
Implied market cap at $0.88: $94.88M
The multi-year forecast depicts a bullish tilt from the later 2020s into the 2030s and beyond. In 2026 the average forecast price is $0.4517 with a neutral sentiment. By 2029 the average is $0.5909 with a bullish read and a max of $0.9324, and by 2030 the average rises to $0.6102 with a max of $0.9972 and a bullish stance, yielding a 35.1% ROI at the max case.
The trajectory continues with 2031 at $0.5954 (ROI 31.8%), 2032 at $0.4806 (ROI 6.4%, neutral), 2033 at $0.544 (ROI 20.4%), 2034 at $0.681 (ROI 50.8%), and 2035 at $0.701 (ROI 55.2%), with bullish sentiment confirming stronger upside.
Further out, the forecast shows a meaningful upside with 2040 averaging $0.8104 (ROI 79.4%) and 2050 averaging $1.30 (ROI 188.7%), with the max by 2050 reaching $2.96. This implies a long-run bullish pathway though the path includes periods of moderation and variability. These are estimates and not guarantees, and risks in price movement can arise from market dynamics, execution, and regulatory factors.
Tap a question to reveal the answer.
Avg $0.6102; min $0.4043; max $0.9972; ROI 35.1%; sentiment BULLISH.
Forecasts show bullish sentiment in 2029, 2030, 2031, 2033, 2034, 2035, and later years, with a 2050 avg of $1.30 and a max of $2.96 (ROI 188.7%). These are estimates, not guarantees.
Yes, the max price by 2050 is $2.96 with an average of $1.30, yielding a long-run bullish outlook.
$0.3381 to $0.6034.
Impact BioMedical Inc. Community Discussion
0Share your Impact BioMedical Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.